About us.
Alzheimer Solutions B.V. is a pioneering company dedicated to combating Alzheimer's Disease (AD) through a systems biology lipidomics approach. We focus on advancing research and solutions for this devastating condition characterized by progressive cognitive decline and significant suffering. Our groundbreaking research utilizes unique postmortem samples from the Netherlands Brain Bank, combining neocortex and blood plasma analyses with high-fat diet-induced obesity and insulin-resistant mouse models. This comprehensive approach allows us to identify biomarkers and develop innovative strategies to prevent, halt, and combat AD.
Alzheimer Solutions B.V. aims to revolutionize global health by integrating disciplines like biomedicine, biochemistry, oncology, artificial intelligence, nutrition, and environmental sciences. Our multi-faceted research includes precision medication based on biomarkers and lifestyle interventions, emphasizing the importance of balanced nutrition and preventive care. By leveraging cutting-edge scientific research and adopting a holistic view, we strive to develop impactful solutions that contribute to a healthier global population. Our mission is to advance preventive measures, slow disease progression, and offer effective treatments, ultimately improving the quality of life for those affected by Alzheimer's Disease.
“Dedicated to pioneering advanced treatments and preventive strategies for Alzheimer's Disease, we strive to revolutionize understanding and combat this complex neurodegenerative disorder.”
Our mission.
At Alzheimer's Solutions B.V., our mission is to pioneer precision medicine and biomarker-driven therapies to combat Alzheimer's disease (AD) from its earliest stages. We focus on identifying and treating AD through cutting-edge lipidomics, targeting multiple pathways to slow disease progression. Our approach emphasizes early detection, effective blood-brain barrier (BBB) passage, and stage-specific interventions. By combining innovative multi-drug therapies and personalized care, we aim to improve outcomes and quality of life for those affected by AD. Next, we employ a drug repositioning strategy. By repurposing existing drugs developed for other conditions, it offers a cost-effective and accelerated approach to AD treatment. This method leverages established safety profiles, bypassing early-stage testing and expediting the drug development process.
Our vision.
At Alzheimer's Solutions B.V., we are committed to turning Alzheimer's disease (AD) from a devastating diagnosis into a manageable condition. We believe in honesty—lost neurons cannot be regained, but we can slow or halt AD progression. Grounded in innovative lipidomics research, we developed a groundbreaking hypothesis that drives our approach. In studying the several AD pathogenesis pathways, we established key preconditions that led us to the most effective anti-AD protocol. This protocol integrates precision lipidomics, targeting multiple distinct pathways of aberrant lipid metabolism in AD involved in neuroinflammation, metabolic dysfunction, and lipid dysregulation. By focusing on early detection, effective drug delivery across the blood-brain barrier, and multi-drug therapies, we aim to revolutionize AD treatment and preserve cognitive health for future generations.
About dr. dr. ir. Vincent van Ginneken.
Dr. dr. ir. Vincent van Ginneken is the esteemed Head Researcher at Alzheimer Solutions. He is a renowned expert in marine biotechnology and environmental science. Dr. van Ginneken holds a PhD from Leiden University in Mathematics and Natural Sciences and a second PhD from Wageningen University in Agricultural Sciences. With over 115 published papers in reputed journals, including Nature, his work spans various disciplines such as biomedical, agricultural, and seaweed biotechnology.
